



**CANACCORD GENUITY STRENGTHENS GLOBAL HEALTHCARE AND TECHNOLOGY CAPABILITY WITH ADDITION OF KEY INVESTMENT BANKING AND RESEARCH PROFESSIONALS**

**TORONTO, May 28, 2015** – Canaccord Genuity (the "Company") is pleased to announce the expansion of its Healthcare and Technology practices with the addition of three senior capital markets professionals. Based in Nashville, the group will focus on the fast growing sectors of Healthcare Information Technology ("HCIT") and Outsourced Healthcare Services.

"Nashville has become a centre of innovation for the global healthcare industry and is home to a diverse collection of dynamic growth companies," commented Dan Daviau, CEO, North American Capital Markets, Canaccord Genuity. "These appointments underscore our commitment to advancing our coverage of relevant growth sectors and delivering best in class equity research, investment banking and advisory expertise across our global platform."

Dudley Baker joins as Managing Director, Investment Banking and brings over 13 years of investment banking, private equity, and corporate development experience to his role. Most recently, he served as Managing Director at Avondale Partners, LLC, where he led coverage of HCIT and Business Services. Previously, he worked at Morgan Joseph Inc. where he focused on healthcare and business services transactions. Dudley holds an MBA from the Owen Graduate School of Management at Vanderbilt University and a B.A. from Rhodes College.

Roger Briggs joins as Managing Director, Investment Banking and brings more than three decades of experience to the team. In addition to supporting the Healthcare investment banking practice, Roger will focus his efforts on building the US financial sponsors coverage. Most recently, Roger was an Operating Partner at Trilantic Capital Partners, a global private equity firm. Previously, he was a Founder and former Head of Investment Banking at Morgan Joseph, Inc.; Head of Investment Banking at SunTrust Equitable Securities; Head of Mergers and Acquisitions at Bankers Trust and a founding member of the Mergers and Acquisitions group at Solomon Brothers. Roger holds a B.S. from Northwestern University.

Richard Close joins the equity research division as a Managing Director and will lead coverage of the HCIT, Supply Chain and Outsourced Healthcare Services sectors. Most recently, Richard was Managing Director and Senior Research Analyst at Avondale Partners, LLC. Prior to this, he worked at Jefferies in a similar capacity for seven years and as an equity research analyst at SunTrust Robinson Humphrey and its predecessor companies for six years. Richard holds a B.S. in Economics from the Rochester Institute of Technology.

Canaccord Genuity's Healthcare & Life Sciences equity research coverage universe is led by 10 research analysts located across three continents providing award-winning global coverage and investment ideas for the Biotechnology, Specialty Pharmaceuticals, Medical Devices, Life Sciences Tools, HCIT and Outsourced Healthcare Services subsectors.

## **ABOUT CANACCORD GENUITY GROUP INC.:**

Through its principal subsidiaries, Canaccord Genuity Group Inc. (the “Company”) is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage services and investment banking services. The Company has offices in 10 countries worldwide, including Wealth Management offices located in Canada, Australia, the UK and Europe. Canaccord Genuity, the international capital markets division, operates in Canada, the US, the UK, France, Ireland, Hong Kong, China, Singapore, Australia and Barbados. To us there are no foreign markets.<sup>TM</sup>

Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange.

## **FOR FURTHER INFORMATION CONTACT:**

### **North America media:**

Scott Davidson

Executive Vice President, Global Head of Corporate Development and Strategy

Phone: 416-869-3875, email: [scott.davidson@canaccord.com](mailto:scott.davidson@canaccord.com)

### **For investor relations inquiries contact:**

Christina Marinoff

Vice President, Investor Relations & Communications

Phone: 416-687-5507, email: [christina.marinoff@canaccord.com](mailto:christina.marinoff@canaccord.com)

### **London media:**

Robert Morgan

Stockwell

Phone: +44 (0) 20 7240 2486, email: [robert.morgan@stockwellgroup.com](mailto:robert.morgan@stockwellgroup.com)

### **Brokers:**

Oliver Hearsey

RBC Europe Limited

Phone: +44 (0) 20 7653 4000, email: [oliver.hearsey@rbccm.com](mailto:oliver.hearsey@rbccm.com)

Simon Hardy or Alex Collins

Jefferies International Limited

Phone: +44 (0) 20 7029 8000, email: [simon.hardy@jefferies.com](mailto:simon.hardy@jefferies.com);

[alex.collins@jefferies.com](mailto:alex.collins@jefferies.com)